Login to Your Account

Theravance Climbs as COPD Program Enters Phase III

By Marie Powers

Friday, February 4, 2011
GlaxoSmithKline plc and Theravance Inc. achieved major milestones this week in a pair of clinical development programs focused on treatments for patients with chronic obstructive pulmonary disease (COPD).

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription